PROG Holdings, Inc. (PRG)

CTI BioPharma Stock Forecast

Stock Price Forecast

The 6 analysts that cover CTI BioPharma stock have a consensus rating of "Buy" and an average price target of $38.83, which forecasts a 27.31% increase in the stock price over the next year. The lowest target is $24 and the highest is $48.

Price Target: $38.83 (+27.31%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$24	$38.83	$45	$48
Change	-21.31%	+27.31%	+47.54%	+57.38%

Analyst Ratings

The average analyst rating for CTI BioPharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	2	2	2	2	2	2
Buy	2	2	2	2	2	2
Hold	2	2	2	2	2	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	1
Total	6	6	6	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Vincent Ciantic BTIG	BTIG	Hold → Strong Sell Downgrades $24	Hold → Strong Sell	Downgrades	$24	-21.31%	Jul 14, 2025
Anthony Chukumba Loop Capital	Loop Capital	Strong Buy Maintains $45 → $40	Strong Buy	Maintains	$45 → $40	+31.15%	Apr 24, 2025
Bradley Thomas Keybanc	Keybanc	Buy Maintains $50 → $45	Buy	Maintains	$50 → $45	+47.54%	Apr 24, 2025
Kyle Joseph Jefferies	Jefferies	Strong Buy → Hold Downgrades $58 → $29	Strong Buy → Hold	Downgrades	$58 → $29	-4.92%	Feb 26, 2025
Kyle Joseph Stephens & Co.	Stephens & Co.	Buy Reiterates $60	Buy	Reiterates	$60	+96.72%	Jan 2, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

2.50B

Increased by 1.56%

from 2.46B

Revenue Next Year

2.60B

Increased by 3.80%

from 2.50B

EPS This Year

3.16

Decreased by -30.34%

from 4.53

EPS Next Year

3.69

Increased by 16.83%

from 3.16

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	2.48B	2.68B	2.60B	2.41B	2.46B	2.50B	2.60B	2.75B
Revenue Growth	14.86%	7.78%	-2.99%	-7.30%	2.29%	1.56%	3.80%	5.97%
EPS	-0.91	3.67	1.90	2.98	4.53	3.16	3.69	4.58
EPS Growth	-	-	-48.23%	56.84%	52.01%	-30.34%	16.83%	24.11%
Forward PE	-	-	-	-	-	9.67	8.27	6.67
No. Analysts	-	-	-	-	-	8	8	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	2.6B	2.8B	3.0B
Avg	2.5B	2.6B	2.8B
Low	2.4B	2.5B	2.6B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	5.8%	12.4%	15.1%
Avg	1.6%	3.8%	6.0%
Low	-1.9%	-2.0%	-1.8%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	3.32	4.31	5.17
Avg	3.16	3.69	4.58
Low	3.02	3.28	4.06

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-26.8%	36.4%	40.1%
Avg	-30.3%	16.8%	24.1%
Low	-33.4%	4.0%	10.1%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.